Top

Published in:

01-06-2016 | Original Article

Mucins MUC16 and MUC1 are major carriers of SLe^a and SLe^x in borderline and malignant serous ovarian tumors

Authors: Sara Ricardo, Lara Marcos-Silva, Cristina Valente, Ricardo Coelho, Rosa Gomes, Leonor David

Published in: Virchows Archiv | Issue 6/2016

Abstract

Mucins are heavily glycosylated proteins overexpressed and associated with truncated or sialylated glycans upon malignant transformation. We previously identified a panel of four glyco-mucin profiles (MUC16/Tn, MUC16/STn, MUC1/Tn, and MUC1/STn) with 100 % specificity and 100 % positive predictive value for detection of borderline/malignant serous tumors of the ovary, using proximity ligation assay (PLA). In the present work, using the same method, we studied other mucin glycosylation profiles that might add relevant information for diagnostic purposes. We used PLA probes to MUC16, MUC1, sialyl Lewis^a (SLe^a), and sialyl Lewis^x (SLe^x) to study a series of 39 ovarian serous tumors (14 adenocarcinomas, 10 borderline ovarian tumors (BOTs), and 15 cystadenomas). Our results demonstrated that, in adenocarcinomas and BOTs, the major carriers of SLe^a and SLe^x are MUC16 and/or MUC1 (100 and 92 % for SLe^a and 64 and 70 % for SLe^x, respectively). In cystadenomas, SLe^a and SLe^x are mainly carried by unidentified proteins (85 and 78 %, respectively). Our study identified, for the first time, the major protein carriers of SLe^a and SLe^x in ovarian adenocarcinomas and BOTs, MUC1 and MUC16, and also that distinct unidentified carriers are involved in cystadenomas. These results emphasize the relevance of multiple biomarker recognition provided by multiplex assays, such as PLA, to enhance sensitivity and specificity of serum and tissue assays.

Available only for authorised users

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France

Hattrup CL, Gendler SJ (2008) Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 70:431–457. doi:10.1146/annurev.physiol.70.113006.100659 CrossRefPubMed

Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L, Gupta R, Bennett EP, Mandel U, Brunak S, Wandall HH, Levery SB, Clausen H (2013) Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. The EMBO J 32(10):1478–1488. doi:10.1038/emboj.2013.79 CrossRefPubMed

Marcos-Silva L, Narimatsu Y, Halim A, Campos D, Yang Z, Tarp MA, Pereira PJ, Mandel U, Bennett EP, Vakhrushev SY, Levery SB, David L, Clausen H (2014) Characterization of binding epitopes of CA125 monoclonal antibodies. J Proteome Res 13(7):3349–3359. doi:10.1021/pr500215g CrossRefPubMed

Zurawski VR Jr., Orjaseter H, Andersen A, Jellum E (1988) Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer J Int Du Cancer 42(5):677–680CrossRef

Capstick V, Maclean GD, Suresh MR, Bodnar D, Lloyd S, Shepert L, Longenecker BM, Krantz M (1991) Clinical evaluation of a new two-site assay for CA125 antigen. Int J Biol Markers 6(2):129–135PubMed

Kan YY, Yeh SH, Ng HT, Lou CM (1992) Effect of menstruation on serum CA125 levels. Asia-Oceania J Obstet Gynaecol/AOFOG 18(4):339–343CrossRef

Timmerman D, Moerman P, Vergote I (1995) Meigs’ syndrome with elevated serum CA 125 levels: two case reports and review of the literature. Gynecol Oncol 59(3):405–408. doi:10.1006/gyno.1995.9952 CrossRefPubMed

Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, Cruz E, Kumar S, Das S, Lele SM, Anderson JM, Wittel UA, Hollingsworth MA, Batra SK (2011) Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One 6(10):e26839. doi:10.1371/journal.pone.0026839 CrossRefPubMedPubMedCentral

10.

Bressan A, Bozzo F, Maggi CA, Binaschi M (2013) OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain. Dis Markers 34(4):257–267. doi:10.3233/DMA-130968 CrossRefPubMedPubMedCentral

11.

Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y (2007) Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 105(3):695–702. doi:10.1016/j.ygyno.2007.02.004 CrossRefPubMed

12.

Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Greggi S, Mancuso S (1988) CA 15-3 as a tumor marker in gynecological malignancies. Gynecol Oncol 30(2):265–273CrossRefPubMed

13.

Duffy MJ (2001) Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 38(3):225–262. doi:10.1080/20014091084218 CrossRefPubMed

14.

Pochechueva T, Jacob F, Fedier A, Heinzelmann-Schwarz V (2012) Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches. Metabolites 2(4). doi:10.3390/metabo2040913

15.

Dabelsteen E (1996) Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 179(4):358–369. doi:10.1002/(sici)1096-9896(199608)179:4<358::aid-path564>3.0.co;2-t CrossRefPubMed

16.

Reis CA, Osorio H, Silva L, Gomes C, David L (2010) Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol 63(4):322–329. doi:10.1136/jcp.2009.071035 CrossRefPubMed

17.

Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, Banks RE, Hutson R, Harvey DJ, Antrobus R, Petrescu SM, Dwek RA, Rudd PM (2007) Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17(12):1344–1356. doi:10.1093/glycob/cwm100 CrossRefPubMed

18.

Ricardo S, Marcos-Silva L, Pereira D, Pinto R, Almeida R, Soderberg O, Mandel U, Clausen H, Felix A, Lunet N, David L (2015) Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Mol Oncol 9(2):503–512. doi:10.1016/j.molonc.2014.10.005 CrossRefPubMed

19.

Simon R, Mirlacher M, Sauter G (2004) Tissue microarrays. Methods Mol Med 97:377–389. doi:10.1385/1-59259-760-2:377 PubMed

20.

Avninder S, Ylaya K, Hewitt SM (2008) Tissue microarray: a simple technology that has revolutionized research in pathology. J Postgrad Med 54(2):158–162CrossRefPubMed

21.

Marcos-Silva L, Ricardo S, Chen K, Blixt O, Arigi E, Pereira D, Hogdall E, Mandel U, Bennett EP, Vakhrushev SY, David L, Clausen H (2015) A novel monoclonal antibody to a defined peptide epitope in MUC16. Glycobiology 25(11):1172–1182. doi:10.1093/glycob/cwv056 CrossRefPubMed

22.

Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, Bodmer WF (1981) Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer J Int Du Cancer 28(1):17–21CrossRef

23.

Motoyama T, Watanabe H, Takeuchi S, Watanabe T, Gotoh S, Okazaki E (1990) Cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors. Cancer 66(12):2628–2635CrossRefPubMed

24.

Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K (2005) Expression of sialyl Lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res 25(3 A):1615–1622PubMed

25.

Pinto R, Carvalho AS, Conze T, Magalhaes A, Picco G, Burchell JM, Taylor-Papadimitriou J, Reis CA, Almeida R, Mandel U, Clausen H, Soderberg O, David L (2012) Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J Cell Mol Med 16(7):1474–1484. doi:10.1111/j.1582-4934.2011.01436.x CrossRefPubMedPubMedCentral

26.

Conze T, Carvalho AS, Landegren U, Almeida R, Reis CA, David L, Soderberg O (2010) MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas. Glycobiology 20(2):199–206. doi:10.1093/glycob/cwp161 CrossRefPubMed

27.

Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, Haab BB (2009) The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics: MCP 8(7):1697–1707. doi:10.1074/mcp.M900135-MCP200 CrossRefPubMedPubMedCentral

28.

Yue T, Maupin KA, Fallon B, Li L, Partyka K, Anderson MA, Brenner DE, Kaul K, Zeh H, Moser AJ, Simeone DM, Feng Z, Brand RE, Haab BB (2011) Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One 6(12):e29180. doi:10.1371/journal.pone.0029180 CrossRefPubMedPubMedCentral

29.

Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Trope CG, Bryne M (2000) Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and sialyl Tn antigen expression in effusions. Hum Pathol 31(9):1081–1087. doi:10.1053/hupa.2000.9776 CrossRefPubMed

30.

Bresalier RS, Ho SB, Schoeppner HL, Kim YS, Sleisenger MH, Brodt P, Byrd JC (1996) Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 110(5):1354–1367CrossRefPubMed

31.

Al Masri A, Gendler SJ (2005) Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis. Oncogene 24(38):5799–5808. doi:10.1038/sj.onc.1208738 CrossRefPubMed

32.

Giannakouros P, Comamala M, Matte I, Rancourt C, Piche A (2015) MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering beta-catenin signaling. Am J Cancer Res 5(1):219–230PubMedPubMedCentral

33.

Akita K, Tanaka M, Tanida S, Mori Y, Toda M, Nakada H (2013) CA125/MUC16 interacts with Src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell-cell adhesion. Eur J Cell Biol 92(8–9):257–263. doi:10.1016/j.ejcb.2013.10.005 CrossRefPubMed

34.

Bitler BG, Goverdhan A, Schroeder JA (2010) MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci 123(Pt 10):1716–1723. doi:10.1242/jcs.062661 CrossRefPubMedPubMedCentral

35.

Comamala M, Pinard M, Theriault C, Matte I, Albert A, Boivin M, Beaudin J, Piche A, Rancourt C (2011) Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 104(6):989–999. doi:10.1038/bjc.2011.34 CrossRefPubMedPubMedCentral

36.

Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, Kitawaki J, Nakanishi H, Narimatsu H, Nakada H (2012) Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 22(4):531–538. doi:10.1097/IGC.0b013e3182473292 CrossRef

37.

Chen K, Gentry-Maharaj A, Burnell M, Steentoft C, Marcos-Silva L, Mandel U, Jacobs I, Dawnay A, Menon U, Blixt O (2013) Microarray glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J Proteome Res 12(3):1408–1418. doi:10.1021/pr3010474 CrossRefPubMed

38.

Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3(12):995–1000. doi:10.1038/nmeth947 CrossRefPubMed

39.

Koos B, Kamali-Moghaddam M, David L, Sobrinho-Simoes M, Dimberg A, Nilsson M, Wahlby C, Soderberg O (2015) Next-generation pathology—surveillance of tumor microecology. J Mol Biol 427(11):2013–2022. doi:10.1016/j.jmb.2015.02.017 CrossRefPubMed

40.

Liu X, Sejbal J, Kotovych G, Koganty RR, Reddish MA, Jackson L, Gandhi SS, Mendonca AJ, Longenecker BM (1995) Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides. Glycoconj J 12(5):607–617CrossRefPubMed

Title: Mucins MUC16 and MUC1 are major carriers of SLea and SLex in borderline and malignant serous ovarian tumors
Authors: Sara Ricardo
Lara Marcos-Silva
Cristina Valente
Ricardo Coelho
Rosa Gomes
Leonor David
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 6/2016
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-016-1929-6

At a glance: The STEP trials

Springer Medicine

Mucins MUC16 and MUC1 are major carriers of SLe^a and SLe^x in borderline and malignant serous ovarian tumors

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review

Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer

Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules

Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival

NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial

In this issue